{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:24:26Z","timestamp":1784899466534,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jhep.2018.07.023","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T21:27:22Z","timestamp":1533763642000},"page":"1221-1230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12\u202fweeks in HCV DAA-experienced patients"],"prefix":"10.1016","volume":"69","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Svarovskia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Doehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.07.023_b0005","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/jvh.12123","article-title":"Viral hepatitis and the Global Burden of Disease: a need to regroup","volume":"20","author":"Cooke","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2018.07.023_b0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.023_b0015","first-page":"161","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"The Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.07.023_b0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.023_b0025","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD IDSA HCV Guidance Panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.023_b0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756283X15587481","article-title":"The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment","volume":"8","author":"Lam","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2018.07.023_b0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/HMER.S55864","article-title":"Interferon-free combination therapies for the treatment of hepatitis C: current insights","volume":"7","author":"Holmes","year":"2015","journal-title":"Hepat Med"},{"key":"10.1016\/j.jhep.2018.07.023_b0040","unstructured":"Nelson DR. HCV-TARGET International Registry Do Phase III Trials Translate into Real World [Presentation]. In: 15th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); 2015 26\u201328 June; Berlin, Germany; 2015."},{"key":"10.1016\/j.jhep.2018.07.023_b0045","unstructured":"Welzel TM, Nelson DR, Morelli G, Di Bisceglie AM, Reddy KR, Kuo A, et al. Safety and Efficacy of Sofosbuvir and Ribavirin for the Treatment of HCV Genotype 2 and 3: Results of the HCV-TARGET Study [Abstract 1057]. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2015 13\u201317 November; San Francisco, CA; 2015. p. 727A\u2013728A."},{"key":"10.1016\/j.jhep.2018.07.023_b0050","unstructured":"Dieterich DT, Bacon B, Curry M, Flamm SL, Guest L, Kowdley K, et al. Ledipasvir\/Sofosbuvir +\/- Ribavirin in Patients Co-infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network [Poster #SAT-134]. In: European Association for the Study of the Liver (EASL); 2016 13\u201317 April; Barcelona, Spain; 2016."},{"key":"10.1016\/j.jhep.2018.07.023_b0055","doi-asserted-by":"crossref","unstructured":"Dieterich DT, Bacon B, Flamm SL, Kowdley K, Milligan S, Tsai N, et al. Final Evaluation of 955 HCV Patients Treated with 12 Week Regimens Containing Sofosbuvir +\/- Simeprevir in the Trio Network: Academic and Community Treatment of a Real-World, Heterogeneous Population [Abstract P0775]. In: Digestive Disease Week (DDW); 2015 17\u201319 May; Washington, DC; 2015.","DOI":"10.1016\/S0168-8278(15)30978-8"},{"key":"10.1016\/j.jhep.2018.07.023_b0060","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Bacon B, Dieterich DT, Flamm SL, Kowdley K, Lawitz E, et al. Evaluation of Access to Care in Patients Prescribed Sofosbuvir-Containing Regimens: Data From the TRIO Network [Abstract Tu1033]. In: Digestive Disease Week 2015 (DDW); 2015 17\u201319 May; Washington, DC; 2015. p. S1090.","DOI":"10.1016\/S0016-5085(15)33722-7"},{"key":"10.1016\/j.jhep.2018.07.023_b0065","doi-asserted-by":"crossref","unstructured":"Dieterich D, Bacon B, Flamm S, Kowley K, Milligan S, Tsai N, et al. Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +\/-simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population [Abstract P0775]. In: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); 2015 22\u201326 April; Vienna, Austria; 2015. p. S621.","DOI":"10.1016\/S0168-8278(15)30978-8"},{"key":"10.1016\/j.jhep.2018.07.023_b0070","article-title":"Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","author":"Wyles","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2018.07.023_b0075","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.02494-12","article-title":"Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0080","doi-asserted-by":"crossref","unstructured":"Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, Svarovskaia E, et al. Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir\/Sofosbuvir-Based Regimens With Ledipasvir\/Sofosbuvir for 24 Weeks. In: European Association for the Study of the Liver (EASL). The 50th International Liver Congress; 2015 April 22\u201326; Vienna, Austria; 2015.","DOI":"10.1016\/S0168-8278(15)30012-X"},{"key":"10.1016\/j.jhep.2018.07.023_b0085","doi-asserted-by":"crossref","unstructured":"Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, et al. Sofosbuvir\/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study [Presentation PS-024]. In: European Association for the Study of the Liver (EASL); 2016 13\u201317 April; Barcelona, Spain; 2016.","DOI":"10.1016\/S0168-8278(16)00037-4"},{"key":"10.1016\/j.jhep.2018.07.023_b0090","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0095","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","article-title":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues","volume":"50","author":"Dutartre","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0100","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase II and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2018.07.023_b0105","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","article-title":"Clinical resistance to velpatasvir (GS-5816), a Novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein","volume":"60","author":"Lawitz","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0110","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","article-title":"In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435","volume":"54","author":"Lenz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0115","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","article-title":"Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0120","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0125","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2018.07.023_b0130","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0135","doi-asserted-by":"crossref","unstructured":"Taylor JG, Appleby T, Barauskas O, Chen X, Dvory-Sobol H, Gong R, et al. Preclinical Profile of the Pangenotypic HCV NS3\/4A Protease Inhibitor GS-9857 [Poster P0899]. In: European Association for the Study of the Liver (EASL). 50th International Liver Congress.; 2015 22\u201326 April; Vienna, Austria; 2015.","DOI":"10.1016\/S0168-8278(15)31102-8"},{"key":"10.1016\/j.jhep.2018.07.023_b0140","unstructured":"Lawitz E, Dvory-Sobol H, Yang JC, Stamm LM, Taylor JG, Brainard DM, et al. Characterization of HCV Resistance From a 3-Day Monotherapy Study of GS-9857, a Novel Pangenotypic NS3\/4A Protease Inhibitor [Poster 718]. In: American Association for the Study of Liver Diseases (AASLD); 2015 13\u201317 November; San Francisco, CA; 2015."},{"key":"10.1016\/j.jhep.2018.07.023_b0145","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hep.25743","article-title":"Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study","volume":"56","author":"Manns","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.07.023_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.antiviral.2011.11.007","article-title":"Molecular modeling study on the resistance mechanism of HCV NS3\/4A serine protease mutants R155K, A156V and D168A to TMC435","volume":"93","author":"Xue","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2018.07.023_b0155","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.bbagen.2012.06.001","article-title":"Understanding the drug resistance mechanism of hepatitis C virus NS3\/4A to ITMN-191 due to R155K, A156V, D168A\/E mutations: a computational study","volume":"1820","author":"Pan","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2018.07.023_b0160","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.023_b0165","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.07.023_b0170","unstructured":"VOSEVI\u2122, Gilead Sciences Incorporated. VOSEVI\u2122 (sofosbuvir, velpatasvir, and voxilaprevir) tablets, for oral use. US Prescribing Information. Foster City, CA Revised: July. In; 2017."},{"key":"10.1016\/j.jhep.2018.07.023_b0175","unstructured":"VOSEVI\u2122, Gilead Sciences Ireland UC. VOSEVI\u2122 400 mg\/100 mg\/100 mg film-coated tablets sofosbuvir\/velpatasvir\/voxilaprevir. Summary of Product Characteristics (SmPC). County Cork, Ireland. Revised: July. In; 2017."},{"key":"10.1016\/j.jhep.2018.07.023_b0180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.023_b0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40261-017-0492-5","article-title":"US FDA perspective on elbasvir\/grazoprevir treatment for patients with chronic hepatitis C virus genotype 1 or 4 infection","volume":"37","author":"Boyd","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jhep.2018.07.023_b0190","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","article-title":"Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir","volume":"152","author":"Komatsu","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.07.023_b0195","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00307-11","article-title":"Mechanistic characterization of GS-9190 (tegobuvir), a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase","volume":"55","author":"Shih","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2018.07.023_b0205","doi-asserted-by":"crossref","first-page":"5289","DOI":"10.1128\/AAC.00780-12","article-title":"Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients","volume":"56","author":"Dvory-Sobol","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2018.07.023_b0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","article-title":"Evolution of treatment-emergent resistant variants in telaprevir phase III clinical trials","volume":"57","author":"Sullivan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2018.07.023_b0215","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2014.10.010","article-title":"Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C","volume":"113","author":"Howe","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2018.07.023_b0220","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.023_b0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","article-title":"Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE","volume":"62","author":"Buti","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2018.07.023_b0230","doi-asserted-by":"crossref","unstructured":"Roberts SK, Cooper CL, Lawitz E, Reddy KR, Thompson AJ, Zeuzem S, et al. SOF\/VEL\/VOX Results in High SVR12 Rates When Administered for 12 Weeks in DAA-Experienced Patients or for 8 Weeks in DAA-Na\u00efve Patients: an Integrated Analysis of the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 Studies [Poster SAT-280]. In: The International Liver Congress\u2122 2017: European Association for the Study of the Liver (EASL); 2017 19\u201323 April; Amsterdam, the Netherlands; 2017.","DOI":"10.1016\/S0168-8278(17)31974-8"},{"key":"10.1016\/j.jhep.2018.07.023_b0235","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/S0168-8278(16)00037-4","article-title":"Sofosbuvir\/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A containing DAA regimens: results of the GS-US-342-1553 study [Abstract PS024]","volume":"64","author":"Gane","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.07.023_b0240","doi-asserted-by":"crossref","unstructured":"Poordad P, Pol S, Asatryan A, Buti M, Shaw D, H\u00e9zode C, et al. MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure [Presentation]. In: The International Liver Congress\u2122 2017: European Association for the Study of the Liver (EASL); 2017 19\u201323 April; Amsterdam, the Netherlands 2017.","DOI":"10.1016\/S0168-8278(17)30432-4"},{"key":"10.1016\/j.jhep.2018.07.023_b0245","doi-asserted-by":"crossref","unstructured":"Pilot-Matias T, Krishnan R, Schnell G, Tripathi R, Beyer J, Reisch T, et al. Resistance Analysis in the MAGELLAN-1 Study (Part 2): Glecaprevir\/Pibrentasvir Therapy in HCV-Infected Patients Who Had Failed Prior DAA Regimens Containing NS3\/4A Protease and\/or NS5A Inhibitors [Presentation SAT-204]. In: The International Liver Congress\u2122 2017: European Association for the Study of the Liver (EASL); 2017 19\u201323 April; Amsterdam, the Netherlands; 2017.","DOI":"10.1016\/S0168-8278(17)31898-6"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818322797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818322797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:34:05Z","timestamp":1759174445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818322797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0168827818322797"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.07.023","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12\u202fweeks in HCV DAA-experienced patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}